Antidepressant Reduced Covid-19 Hospitalisation Risk: Study
Umer Jamshaid Published October 28, 2021 | 09:10 AM
Paris, (UrduPoint / Pakistan Point News - 28th Oct, 2021 ) :Treating high-risk Covid-19 patients with the antidepressant fluvoxamine may reduce the risk of prolonged hospitalisation by up to a third, a large-scale study showed Thursday.
Authors said the research could help boost low-cost protection against severe sickness or death in countries that have yet to receive adequate vaccine doses during a grossly uneven rollout.
Fluvoxamine is traditionally used to treat mental health conditions such as depression and obsessive-compulsive disorders and was selected for trial due to its anti-inflammatory properties.
Many problems stemming from Covid are caused by swelling as the immune system over-reacts to the infection.
Writing in the journal The Lancet Public Health, researchers from North and South America, described results in nearly 1,500 Covid-19 outpatients in Brazil.
Of the 741 people that received fluvoxamine, 79 -- just over 10 percent -- had an extended stay in hospital.
Of the 756 who received a placebo, 119 (15.7 percent) were hospitalised.
Authors said that administering fluvoxamine resulted in a relative reduction in hospitalisations of 32 percent.
"Covid-19 still poses a risk to individuals in countries with low resources and limited access to vaccinations," said Edward Mills of McMaster University, co-principal investigator on the trial.
"Identifying inexpensive, widely available, and effective therapies against Covid-19 is therefore of great importance, and repurposing existing medications that are widely available and have well-understood safety profiles is of particular interest." Although reducing deaths was not an intended area of focus, the study also found that 12 patients in the placebo group ended up dying, while just one from the fluvoxamine group succumbed to the virus.
The authors stressed that further evaluation is needed as fluvoxamine isn't on the World Health Organization's list of essential medicines and can be addictive.
"Given fluvoxamine's safety, tolerability, ease of use, low cost, and widespread availability, these findings may have an important influence on national and international guidelines on clinical management of Covid-19," said Gilmar Reis, study co-lead, based in Belo Horizonte, Brazil.
Related Topics
Recent Stories
HEC reviews curricula for environmental sciences degree programme
ICC Asia looking forward to an action-packed Asia Cricket Week
Yuvraj Singh named ICC Men’s T20 World Cup 2024 Ambassador
Greece hands Olympic flame to 2024 Paris Games hosts
Two Kyiv hospitals evacuating over feared Russian strikes
World must act on neurotech revolution, say experts
Charles & Catherine's cancer diagnoses
Champions Alcaraz and Sabalenka through in Madrid Open
King Charles to resume some public duties during cancer treatment: palace
US defense chief announces $6 bn in security aid for Ukraine
Heavy rains cause damage to Spezand-Taftan railway track
Woman stabbed in Israel, attacker killed: police
More Stories From Miscellaneous
-
Modern Education Techniques: A pathway to achieve economic development
15 hours ago -
Kite Flying: From cultural festival to deadly sport
16 hours ago -
PDMA predicts gusty wind, rain with thunder, hails
3 days ago -
Iranian president Raisi given guard of honour at PM House
5 days ago -
Intellectuals, writers accolades Naseer Mirza on his literary contribution
5 days ago -
Bahawalpur Adabi Sangat hosts memorable mushaira
5 days ago
-
Cattle farming vital to alleviate poverty in rural areas
5 days ago -
Pakistan: A land of tourism, archeological wonders
6 days ago -
Transforming education sector: from job hunters to job creators
8 days ago -
Amjad Bobby remembered on 19th death anniversary for timeless contributions to music
12 days ago -
Legendary actor Nadeem’s 26 films released on Eid-ul-Fitr days in 50 years
12 days ago -
Besant Hall Cultural Centre to celebrate evening with Sanam Marvi on 26 April
12 days ago